Compare NC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | VNDA |
|---|---|---|
| Founded | 1913 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.8M | 387.9M |
| IPO Year | 2006 | 2005 |
| Metric | NC | VNDA |
|---|---|---|
| Price | $51.71 | $6.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 8.2K | ★ 875.4K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | $104,778,000.00 | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | $44.20 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $35.43 | $4.14 |
| 52 Week High | $59.42 | $9.91 |
| Indicator | NC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.36 | 46.94 |
| Support Level | $47.33 | $5.97 |
| Resistance Level | $54.23 | $6.73 |
| Average True Range (ATR) | 1.61 | 0.25 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 54.20 | 60.45 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments: Utility Coal Mining, Contract Mining, and Minerals and Royalties. The Utility Coal Mining segment, operated by North American Coal, manages surface coal mines that are exclusive, long-term fuel providers for power generation companies. The Contract Mining segment, operated by North American Mining, is a provider of a broad range of specialized, long-term contract mining services. The Minerals and Royalties segment, which includes the Catapult Mineral Partners (Catapult) business, acquires and promotes the development of mineral and royalty interests and other related investments.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.